RNAZ

TransCode Therapeutics, Inc. (RNAZ) | Rumor.io

TransCode Therapeutics

RNAZ

Attention (50-day avg)0%

Attention rank (50-day avg)#2,350

Bullish sentiment (50-day avg)77%

Price to earnings ratio0

Market capitalization29M

Earnings per share-48.3

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-34.7M

Social

What share of all stock conversation is about RNAZ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% -0.01

Aug 31

TransCode Therapeutics has announced a publication demonstrating the survival benefit of its lead candidate TTX-MC138 in a preclinical model of breast cancer bone metastasis.
The company maintains a live equity line and an effective shelf registration, which provide immediate mechanisms to sell shares into price strength.
The publication has led to a significant increase in the share price, with the stock surging to $3.00 pre-market before dropping back down to $1.74.

Generated by AI

Sentiment

Of the messages about RNAZ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	84.62% -1.1	72% -10.61	72.38% -5.69
Bearish	—	15.38% +1.1	28% +10.61	27.62% +5.69

Bullish· Jun 3

$RNAZ has the potential to recover to $16 following a positive result in trial 2.
The stock's low float of 950K and current price of $5.37 make it an attractive bottom play.
A break above the VWAP could lead to a significant price increase, with some analysts predicting a finish above $5.

Bearish· Jun 3

The stock may experience dilution, potentially negatively impacting shareholder value.
The company's recent Phase 1 results, while a step forward, still require significant work and may not be enough to sustain investor interest.
The stock's recent price drop may be attributed to the sale of shares by major investors, such as CK Life Sciences.

Generated by AI

Topics

Of the messages about RNAZ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	93.1%	90%	38.07%
Technical Analysis	0%	3.45%	7.5%	30.97%
Analysts	0%	0%	0%	18.88%
Controversies	0%	3.45%	2.5%	0.15%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	11.93%

Announcements· Feb 5

TransCode Therapeutics submitted an IND amendment to the FDA for a planned Phase 2a clinical trial with its lead candidate TTX-MC138, expanding testing into colorectal cancer minimal residual disease.
The Phase 2a study is projected to start in H1 2026 and marks a potential expansion path for the company's lead program.
The IND amendment was submitted in collaboration with Quantum Leap Healthcare and represents a significant step forward for TransCode Therapeutics' lead therapeutic candidate, TTX-MC138.

Technical Analysis· Feb 5

$RNAZ has seen its entire float traded, with current volume at 2.4M+ shares, driven by momentum from an IND amendment catalyst for Phase 2a Trial of TTX-MC138 in Colorectal Cancer.
The stock has been in a bullish trend, with buyers remaining active as price moves higher and pullbacks being bought; a close above the PMH range at 12.60 is needed to confirm the uptrend.
$RNAZ is attempting to break out of a pennant formation, with the VWAP (Volume-Weighted Average Price) being a key resistance level; a close above the VWAP is necessary for the stock to continue its upward momentum.

Generated by AI

Community

Of the messages about RNAZ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	90.48%	90.16%	88.98%	46.46%
Newcomers	9.52%	9.84%	11.02%	53.54%

Regulars· Feb 5

The company has submitted an IND amendment for a Phase 2a clinical trial with its lead therapeutic, TTX-MC138, in Colorectal Cancer.
The IND amendment has triggered significant price movement, with the stock up 52% premarket and 60% so far, with traders buying on pullbacks and anticipating further catalysts.
The Phase 2a trial expansion path is seen as a bigger data opportunity, with the stock's momentum remaining bullish and traders expecting the price to break through resistance and the VWAP.

Newcomers· Feb 9

The breakout in $RNAZ is confirmed by a decisive breach of the $9.69 resistance on 46K+ volume, with a +22.77% surge.
The commercial launch of $RNAZ is successful, backed by a key IND amendment for a Phase 2a trial, which is seen as a high-conviction, technical breakout in the immuno-oncology space.
$RNAZ's momentum is fueled by the IND amendment submission for its Phase 2a trial, with a target of $14.15 in play, and the company's oncology pipeline advancing.

Generated by AI

Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalystsORLANDO, FL / ACCESS Newswire / September 16, 2026 / RedChip Companies will host an investor webinar today, September 16, 2026, at 4:15 p. ET with TransCode Therapeutics, Inc.

13d agoYahoo Finance

Transcode Therapeutics announces CFO resignation and interim appointment

18d agoInvesting.com

Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalystsORLANDO, FL / ACCESS Newswire / September 3, 2026 / RedChip Companies will host an investor webinar on Wednesday, September 16, 2026, at 4:15 p. ET with TransCode Therapeutics, Inc.

26d agoca.finance.yahoo.com

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

1mo agoYahoo! Finance Canada

TransCode Therapeutics Updates Preferred Stock Governance Terms

Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

TransCode Therapeutics Updates Preferred Stock Ownership Limits

Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about RNAZ also mention

#	Name	Attention
1	Allarity Therapeutics Inc.ALLR	0%-0.01
2	SciSparc Ltd.SPRC	0%+0
3	BSFC - Blue Star Foods Corp.	——
4	LMDX - LumiraDx Limited	——
5	Wheeler Real Estate Investment Trust, Inc.WHLR	0%+0
6	Wheeler Real Estate Investment Trust, Inc. 8.75% Preferred StockWHLRD	0%0
7	Femasys Inc.FEMY	0%+0
8	CNXA - Connexa Sports Technologies Inc.	——
9	Cardio Diagnostics Holdings, Inc.CDIO	0%0
10	HeartSciences Inc.HSCS	0%0

TransCode Therapeutics, Inc.

Healthcare
Biotechnology

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies and immuno-oncology programs for high-risk and advanced cancers. The company’s current work centers on targeted cancer therapeutics designed to address metastatic disease, including candidates that modulate microRNA pathways and other genetic mechanisms linked to tumor growth and spread. Its pipeline also includes programs exploring RNA delivery platforms and combination approaches aimed at improving how nucleic-acid medicines reach cancer cells. TransCode Therapeutics operates within the oncology and RNA therapeutics segments of the life sciences market, where it contributes to the development of precision treatments for difficult-to-treat malignancies. Headquartered in Boston, Massachusetts, the company concentrates on advancing experimental cancer therapies through clinical and preclinical development.

Website

Location

6 Liberty Square

Boston, MA, 02109

United States

Social

What share of all stock conversation is about RNAZ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% -0.01

Aug 31

TransCode Therapeutics has announced a publication demonstrating the survival benefit of its lead candidate TTX-MC138 in a preclinical model of breast cancer bone metastasis.
The company maintains a live equity line and an effective shelf registration, which provide immediate mechanisms to sell shares into price strength.
The publication has led to a significant increase in the share price, with the stock surging to $3.00 pre-market before dropping back down to $1.74.

Generated by AI

Sentiment

Of the messages about RNAZ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	84.62% -1.1	72% -10.61	72.38% -5.69
Bearish	—	15.38% +1.1	28% +10.61	27.62% +5.69

Bullish· Jun 3

$RNAZ has the potential to recover to $16 following a positive result in trial 2.
The stock's low float of 950K and current price of $5.37 make it an attractive bottom play.
A break above the VWAP could lead to a significant price increase, with some analysts predicting a finish above $5.

Bearish· Jun 3

The stock may experience dilution, potentially negatively impacting shareholder value.
The company's recent Phase 1 results, while a step forward, still require significant work and may not be enough to sustain investor interest.
The stock's recent price drop may be attributed to the sale of shares by major investors, such as CK Life Sciences.

Generated by AI

Topics

Of the messages about RNAZ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	93.1%	90%	38.07%
Technical Analysis	0%	3.45%	7.5%	30.97%
Analysts	0%	0%	0%	18.88%
Controversies	0%	3.45%	2.5%	0.15%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	11.93%

Announcements· Feb 5

TransCode Therapeutics submitted an IND amendment to the FDA for a planned Phase 2a clinical trial with its lead candidate TTX-MC138, expanding testing into colorectal cancer minimal residual disease.
The Phase 2a study is projected to start in H1 2026 and marks a potential expansion path for the company's lead program.
The IND amendment was submitted in collaboration with Quantum Leap Healthcare and represents a significant step forward for TransCode Therapeutics' lead therapeutic candidate, TTX-MC138.

Technical Analysis· Feb 5

$RNAZ has seen its entire float traded, with current volume at 2.4M+ shares, driven by momentum from an IND amendment catalyst for Phase 2a Trial of TTX-MC138 in Colorectal Cancer.
The stock has been in a bullish trend, with buyers remaining active as price moves higher and pullbacks being bought; a close above the PMH range at 12.60 is needed to confirm the uptrend.
$RNAZ is attempting to break out of a pennant formation, with the VWAP (Volume-Weighted Average Price) being a key resistance level; a close above the VWAP is necessary for the stock to continue its upward momentum.

Generated by AI

Community

Of the messages about RNAZ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	90.48%	90.16%	88.98%	46.46%
Newcomers	9.52%	9.84%	11.02%	53.54%

Regulars· Feb 5

The company has submitted an IND amendment for a Phase 2a clinical trial with its lead therapeutic, TTX-MC138, in Colorectal Cancer.
The IND amendment has triggered significant price movement, with the stock up 52% premarket and 60% so far, with traders buying on pullbacks and anticipating further catalysts.
The Phase 2a trial expansion path is seen as a bigger data opportunity, with the stock's momentum remaining bullish and traders expecting the price to break through resistance and the VWAP.

Newcomers· Feb 9

The breakout in $RNAZ is confirmed by a decisive breach of the $9.69 resistance on 46K+ volume, with a +22.77% surge.
The commercial launch of $RNAZ is successful, backed by a key IND amendment for a Phase 2a trial, which is seen as a high-conviction, technical breakout in the immuno-oncology space.
$RNAZ's momentum is fueled by the IND amendment submission for its Phase 2a trial, with a target of $14.15 in play, and the company's oncology pipeline advancing.

Generated by AI

TransCode Therapeutics

Social

Aug 31

Bullish· Jun 3

Bearish· Jun 3

Announcements· Feb 5

Technical Analysis· Feb 5

Regulars· Feb 5

Newcomers· Feb 9

Join Today's Live Investor Webinar with TransCode Therapeutics

Transcode Therapeutics announces CFO resignation and interim appointment

Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

TransCode Therapeutics Updates Preferred Stock Governance Terms

TransCode Therapeutics Updates Preferred Stock Ownership Limits

Also Discussed

TransCode Therapeutics, Inc.

Company Information

Location

Join Today's Live Investor Webinar with TransCode Therapeutics

Transcode Therapeutics announces CFO resignation and interim appointment

Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

TransCode Therapeutics Updates Preferred Stock Governance Terms

TransCode Therapeutics Updates Preferred Stock Ownership Limits

Also Discussed

Social

Aug 31

Bullish· Jun 3

Bearish· Jun 3

Announcements· Feb 5

Technical Analysis· Feb 5

Regulars· Feb 5

Newcomers· Feb 9